Pharmacovigilance of biopharmaceuticals: Challenges remain

Drug Safety

Volumn 32, Issue 10, 2009, Pages 811-817

  Giezen, Thijs J ^a,b   Mantel Teeuwisse, Aukje K ^a,b   Leufkens, Hubert G M ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INTERFERON; IMMUNOMODULATING AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; MOUSE INTERFERON; NATURAL PRODUCT; RECOMBINANT DNA; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HUMAN INSULIN; RECOMBINANT THROMBOPOIETIN; SMALL MOLECULE TRANSPORT AGENT; TGN 1412; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

COMPLEX FORMATION; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG APPROVAL; DRUG PURIFICATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG SURVEILLANCE PROGRAM; HUMAN; IMMUNOGENICITY; IMMUNOPHARMACOLOGY; LEUKEMIA; NEOPLASM; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PURE RED CELL ANEMIA; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK MANAGEMENT; SIDE EFFECT; THROMBOCYTOPENIA; TUBERCULOSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; BIOLOGICAL PRODUCTS; BIOPHARMACEUTICS; CAUSALITY; HUMANS; PHARMACOEPIDEMIOLOGY; REGISTRIES; RISK MANAGEMENT; SAFETY;

EID: 69849112772     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11316550-000000000-00000     Document Type: Review

References (32)

1. Schellekens H. How similar do 'biosimilars' need to be? Nat Biotechnol 2004 Nov; 22 (11): 1357-9
2. Crommelin DJ, Storm G, Verrijk R, et al. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003 Nov; 266 (1-2): 3-16
3. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 2004 Jul; 16 (4): 393-8
4. Imperato AK, Smiles S, Abramson SB. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol 2004 May; 16 (3): 199-205
5. Schellekens H. Immunologic mechanisms of EPOassociated pure red cell aplasia. Best Pract Res Clin Haematol 2005 Sep; 18 (3): 473-80
6. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006 Sep; 355 (10): 1018-28
7. Brennan FR, Shaw L, Wing MG, et al. Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges. Mol Biotechnol 2004 May; 27 (1): 59-74
8. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006; 21 Suppl. 5: v9-12
9. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002 Jun; 1 (6): 457-62
10. Ryff JC, Schellekens H. Immunogenicity of rDNA-derived pharmaceuticals. Trends Pharmacol Sci 2002 Jun; 23 (6): 254-6
11. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004 Jul; 329 (7456): 44-7
12. Committee for Medicinal Products for Human Use. Guideline on risk management systems for medicinal products for human use. London: European Medicines Agency, Nov 2005
13. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002 May; 287 (17): 2215-20
14. Bakke OM, Manocchia M, de Abajo F, et al. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 1995 Jul; 58 (1): 108-17
15. Meyboom RHB, Gribnau FWJ, Hekster YA, et al. Characteristics of topics in pharmacovigilance in The Netherlands. Clin Drug Invest 1996; 12: 207-19
16. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Safetyrelated regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008 Oct; 300 (16): 1887-96
17. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006 May; 29 (5): 385-96
18. Meyboom RH, Egberts AC, Gribnau FW, et al. Pharmacovigilance in perspective. Drug Saf 1999 Dec; 21 (6): 429-47
19. Meyboom RH, Hekster YA, Egberts AC, et al. Causal or casual? The role of causality assessment in pharmaco-vigilance. Drug Saf 1997 Dec; 17 (6): 374-89
20. Jones JL, Loftus Jr EV. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007 Oct; 13 (10): 1299-307
21. Meyboom RHB, Star K, Bate J, et al. TNF-a inhibitors and leukaemia: international pharmacovigilance reports. Drug Saf 2008 May; 31 (5): 445-7
22. Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004 Aug; 39 (3): 295-9
23. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004 Oct; 31 (10): 1955-8
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline pharma-covigilance planning E2E, 18 November 2004 [online]. Available from URL: http://www.ich.org/LOB/media/ MEDIA1195.pdf [Accessed 2009 Jul 24]
25. Giezen TJ, Mantel-Teeuwisse AK, Leufkens HGM, et al. Risk management of biopharmaceuticals: a regulatory perspective. Eur J Hosp Pharm Pract 2007; 6: 72-4
26. Boren EJ, Cheema GS, Naguwa SM, et al. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008 Feb-Mar; 30 (1-2): 90-8
27. European Commission. Volume 9A of the rules governing medicinal products in the European Union: guidelines on pharmacovigilance for medicinal products for human use. March 2007 [online]. Available from URL: http://ec.euro pa.eu/enterprise/pharmaceuticals/eudralex/vol-9/pdf/vol9A- 2007-04.pdf [Accessed 2009 Jul 24]
28. Frank RG. Regulation of follow-on biologics. N Engl J Med 2007 Aug; 357 (9): 841-3
29. Baumann A. Early development of therapeutic biologicspharmacokinetics. Curr Drug Metab 2006 Jan; 7 (1): 15-21
30. Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 2005 Sep-Oct; 23 (5 Suppl. 39): S205-7
31. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 May; 295 (19): 2275-85
32. Committee for Medicinal Products for Human Use. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant erythropoietins. London: European Medicines Agency, 2006 Mar